Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan

Fig. 3

Migration capacity of MSCs to B cell lymphoma in vitro and in vivo. a Representative photographs showed the migrated MSCs stained with crystal violet in vitro migration assays. Culture medium (CM), served as a negative control. Scale bar = 200 μm. b The numbers of migrated MSCs in three independent assays were expressed as mean ± SD. c Schematic representation of lentiviral expression vector for firefly luciferase (Luc). d MSC-Luc expressed Luc constitutively in vitro. e Tropism of MSCs to tumor site. MSC-Luc was intravenously injected into tumor-bearing mice. The mice were anesthetized in the indicated time and received intraperitoneal injection of d-luciferin at a dose of 150 μg of d-luciferin per gram of body weight. Ten minutes later, the BLI for luciferase activity was detected by Xenogen in vivo imaging system. M1, M2, M3: represented three mice

Back to article page